Lundbeck hunts for new success drugs in niche diseases
Following a large reorganization of Lundbeck's R&D department, Lundbeck is ready to lift the veil on its future focus areas.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The industry has seen it coming for some time, but in its most recent fiscal report, Lundbeck establishes: The Danish pharmaceutical company will be targeting niches in neurology and psychiatry going forward.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck CEO's pay cut in half in 2020
For subscribers
Lundbeck: acquisitions must be well considered
For subscribers
.jpg&w=384&q=75)
